{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=9", "query": { "condition": "Carcinoma, Pancreas", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 2231, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:43:30.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04058964", "title": "Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Pegylated Recombinant Human Hyaluronidase PH20", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-02-01", "completion_date": "2022-10-31", "has_results": false, "last_update_posted_date": "2020-03-13", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058964" }, { "nct_id": "NCT00889187", "title": "Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Neoadjuvant Short-Course Photon Radiation", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2009-12", "completion_date": "2011-12-30", "has_results": true, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00889187" }, { "nct_id": "NCT01938716", "title": "Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-03", "completion_date": "2019-06-03", "has_results": true, "last_update_posted_date": "2020-11-05", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938716" }, { "nct_id": "NCT00050349", "title": "EPO906 in Carcinoid and Other Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoid", "Neuroendocrine Tumors" ], "interventions": [ { "name": "EPO906 epothilone B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2002-07", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 5, "location_summary": "Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050349" }, { "nct_id": "NCT02646748", "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "itacitinib", "type": "DRUG" }, { "name": "INCB050465", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2016-01-25", "completion_date": "2020-11-20", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 17, "location_summary": "San Francisco, California • Santa Monica, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646748" }, { "nct_id": "NCT02677038", "title": "Olaparib in Treating Patients With Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-11-11", "completion_date": "2022-07-18", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677038" }, { "nct_id": "NCT05254171", "title": "Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Cancer Metastatic", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer Stage IV" ], "interventions": [ { "name": "SBP-101", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Panbela Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2022-08-08", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 14, "location_summary": "Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05254171" }, { "nct_id": "NCT02020252", "title": "Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Gastric Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Testing an interactive technology in a diverse health literary population", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2013-11-26", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020252" }, { "nct_id": "NCT05199584", "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors With PTCH1 Loss-of-function Mutations" ], "interventions": [ { "name": "ENV-101 (taladegib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-24", "completion_date": "2024-02-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199584" }, { "nct_id": "NCT01013649", "title": "Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Intraductal Papillary-Mucinous Neoplasm", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 546, "start_date": "2010-04-05", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-15T06:43:30.995Z", "location_count": 678, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013649" } ] }